"Cardiomyopathies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
Descriptor ID |
D009202
|
MeSH Number(s) |
C14.280.238
|
Concept/Terms |
Cardiomyopathies- Cardiomyopathies
- Cardiomyopathy
- Myocardial Diseases
- Disease, Myocardial
- Diseases, Myocardial
- Myocardial Disease
- Myocardiopathies
- Myocardiopathy
Cardiomyopathies, Secondary- Cardiomyopathies, Secondary
- Cardiomyopathy, Secondary
- Secondary Cardiomyopathies
- Secondary Cardiomyopathy
- Secondary Myocardial Diseases
- Disease, Secondary Myocardial
- Diseases, Secondary Myocardial
- Myocardial Disease, Secondary
- Secondary Myocardial Disease
- Myocardial Diseases, Secondary
Cardiomyopathies, Primary- Cardiomyopathies, Primary
- Cardiomyopathy, Primary
- Primary Cardiomyopathies
- Primary Cardiomyopathy
- Primary Myocardial Diseases
- Myocardial Diseases, Primary
- Disease, Primary Myocardial
- Diseases, Primary Myocardial
- Myocardial Disease, Primary
- Primary Myocardial Disease
|
Below are MeSH descriptors whose meaning is more general than "Cardiomyopathies".
Below are MeSH descriptors whose meaning is more specific than "Cardiomyopathies".
This graph shows the total number of publications written about "Cardiomyopathies" by people in this website by year, and whether "Cardiomyopathies" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1995 | 0 | 1 | 1 |
1996 | 1 | 0 | 1 |
1997 | 1 | 1 | 2 |
1998 | 2 | 0 | 2 |
1999 | 2 | 0 | 2 |
2000 | 3 | 0 | 3 |
2001 | 3 | 0 | 3 |
2002 | 4 | 1 | 5 |
2003 | 5 | 2 | 7 |
2004 | 5 | 0 | 5 |
2005 | 3 | 5 | 8 |
2006 | 11 | 2 | 13 |
2007 | 10 | 8 | 18 |
2008 | 8 | 5 | 13 |
2009 | 7 | 1 | 8 |
2010 | 5 | 3 | 8 |
2011 | 5 | 3 | 8 |
2012 | 10 | 2 | 12 |
2013 | 8 | 1 | 9 |
2014 | 16 | 8 | 24 |
2015 | 12 | 4 | 16 |
2016 | 19 | 2 | 21 |
2017 | 7 | 4 | 11 |
2018 | 13 | 2 | 15 |
2019 | 19 | 1 | 20 |
2020 | 14 | 4 | 18 |
2021 | 19 | 1 | 20 |
2022 | 14 | 0 | 14 |
2023 | 19 | 0 | 19 |
2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cardiomyopathies" by people in Profiles.
-
Altered myocardial lipid regulation in junctophilin-2-associated familial cardiomyopathies. Life Sci Alliance. 2024 May; 7(5).
-
Tachycardia and Atrial Fibrillation-Related Cardiomyopathies: Potential Mechanisms and Current Therapies. JACC Heart Fail. 2024 Apr; 12(4):605-615.
-
Genetic inactivation of ?-catenin is salubrious, whereas its activation is deleterious in desmoplakin cardiomyopathy. Cardiovasc Res. 2023 12 30; 119(17):2712-2728.
-
Nonsense Variant PRDM16-Q187X Causes Impaired Myocardial Development and TGF-? Signaling Resulting in Noncompaction Cardiomyopathy in Humans and Mice. Circ Heart Fail. 2023 12; 16(12):e010351.
-
Programmatic approach to patients with advanced ischemic cardiomyopathy: Integrating microaxial support into strategies for the modern era. Artif Organs. 2024 Jan; 48(1):6-15.
-
Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies. Eur J Heart Fail. 2023 Dec; 25(12):2144-2163.
-
State-of-the-Art Imaging of Infiltrative Cardiomyopathies: A Scientific Statement From the American Heart Association. Circ Cardiovasc Imaging. 2023 11; 16(11):e000081.
-
Insights into Myocardial Fibrosis in Advanced Chronic Kidney Disease Using Human Tissue. Kidney360. 2023 11 01; 4(11):1531-1533.
-
A human mitofusin 2 mutation can cause mitophagic cardiomyopathy. Elife. 2023 11 01; 12.
-
SGLT2 Inhibitor Use and Risk of Clinical?Events in Patients With Cancer Therapy-Related Cardiac Dysfunction. JACC Heart Fail. 2024 Jan; 12(1):67-78.